This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals (NCT05997290), a na phase 2, phase 3 study. The primary outcome is Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSA.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT05997290 |
| Phase | Phase 2, Phase 3 |
| Condition | SARS-CoV-2 Infection, COVID-19 |
| Allocation | Not applicable (single group) |
| Design model | Single Group |
| Masking | None (open label) |
| Enrollment | 1051 |
| Arms in the primary outcome | n/a |
| Lead sponsor | BioNTech SE |
| Results posted | Yes |
2. Clinical Question
Population
The study enrolled healthy participants aged 12 years and older across several substudies and age groups. Substudy A involved people who had received at least 3 doses of a US-authorized mRNA COVID-19 vaccine, with their most recent dose an Omicron BA.4/BA.5-adapted bivalent vaccine received at least 150 days before study vaccination. Substudy B involved COVID-19 vaccine-naïve people with a prior positive SARS-CoV-2 test result more than 28 days before vaccination. Substudy C included age-defined cohorts receiving the JN.1 or KP.2 candidate.
Intervention
Participants received one of three BNT162b2 candidates: Omi XBB.1.5, Omi JN.1, or Omi KP.2. The described arms received a single 30 µg dose at Visit 1. The XBB.1.5 candidate was used in Substudies A and B; JN.1 and KP.2 were used in Substudy C.
Comparator
The registry describes a single-group study with no randomized allocation and no like-for-like control comparison. Participants in different substudies or age cohorts should not be treated as randomized treatment groups. Differences between their outcomes could reflect differences in population, prior vaccination or exposure, age, or other factors, not necessarily the vaccine candidate.
Primary question
The named primary endpoint asks what percentage of participants in Substudy A had a local reaction during Day 1 to Day 7 after vaccination. Reactions were pain at the injection site, redness, or swelling. The broader study purpose was to assess safety, tolerability, and immunogenicity of the candidates. The registry record does not report the primary endpoint’s numerical result or confidence interval.
3. Trial Design
This was a Phase 2/3, single-group study sponsored by BioNTech SE. The registry lists enrollment of 1051 and a status of completed. The listed study start date is 2023-08-10, and the primary completion date is 2025-03-13. Allocation is recorded as not applicable, and masking is listed as none. The design therefore does not support a randomized comparison between vaccine candidates or against a control group.
The study included three substudies and five described groups. Substudy A had participants aged 12 to 17 years, 18 to 55 years, and older than 55 years; these groups received BNT162b2 (Omi XBB.1.5). Substudy B had the same age groupings and used the same candidate. Substudy C included a 12-to-17-year cohort and an 18-to-55-year and older-than-55-year combined group for BNT162b2 (Omi JN.1), as well as 18-to-55-year and older-than-55-year groups for BNT162b2 (Omi KP.2). The arm descriptions state a single 30 µg dose at Visit 1.
The registry summary describes about 6 months of participation, at least 5 clinic visits, blood sampling at each clinic visit, and at least 1 nasal swab. The available summary is incomplete for Substudy C, so its full visit and sampling procedures are not reported in the registry record. The registry record also does not report the rationale for the selected enrollment, detailed eligibility criteria for every cohort, or any additional design features beyond those stated.
Because there was no randomized control arm, the study’s reported outcomes are descriptive observations within the enrolled groups. The different groups had different eligibility histories and age compositions. Comparing their results as though they differed only in the vaccine received would not be justified by this design.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: SSA: A total of 417 participants were assigned, out of which 412 were vaccinated. SSB: A total of 311 participants were assigned and vaccinated. SSC: A total of 321 participants were assigned, out of which 318 were vaccinated. As per study objectives, arms for SSC cohort 1 and 2 have been combined.
Only the first 6 of 11 groups are shown.
Overall Study
| Stage | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | SSB - Group 1: 12-17 Years | SSB - Group 2: 18-55 Years | SSB - Group 3: >55 Years |
|---|---|---|---|---|---|---|
| STARTED | 30 | 177 | 210 | 9 | 253 | 49 |
| Safety Population | 30 | 174 | 208 | 9 | 253 | 49 |
| Evaluable Immunogenicity Population | 27 | 167 | 188 | 9 | 243 | 47 |
| COMPLETED | 29 | 172 | 203 | 9 | 225 | 44 |
| NOT COMPLETED | 1 | 5 | 7 | 0 | 28 | 5 |
Reasons for not completing this period:
| Reason | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | SSB - Group 1: 12-17 Years | SSB - Group 2: 18-55 Years | SSB - Group 3: >55 Years |
|---|---|---|---|---|---|---|
| Withdrawal by Subject | 1 | 0 | 2 | 0 | 6 | 1 |
| Protocol Violation | 0 | 0 | 2 | 0 | 0 | 0 |
| Lost to Follow-up | 0 | 2 | 0 | 0 | 22 | 4 |
| Death | 0 | 0 | 1 | 0 | 0 | 0 |
| Assigned but not vaccinated | 0 | 3 | 2 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 |
Analysis population for the primary outcome, as defined in the registry: Safety population included all participants who received the study intervention. Here, "Overall Number of Participants Analyzed" signifies number of participants reporting at least 1 response in the e-diary.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
Population: Baseline analysis population was evaluated on safety population which included all participants who received the study intervention.
Only the first 6 of 12 groups are shown.
| Characteristic | Unit | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | SSB - Group 1: 12-17 Years | SSB - Group 2: 18-55 Years | SSB - Group 3: >55 Years |
|---|---|---|---|---|---|---|---|
| Participants analysed | 30 | 174 | 208 | 9 | 253 | 49 | |
| Age, Customized: Age – 12-17 Years | Participants | 30 | 0 | 0 | 9 | 0 | 0 |
| Age, Customized: Age – 18-64 Years | Participants | 0 | 174 | 63 | 0 | 253 | 27 |
| Age, Customized: Age – 65-84 Years | Participants | 0 | 0 | 143 | 0 | 0 | 22 |
| Age, Customized: Age – Greater than or equal to 85 Years | Participants | 0 | 0 | 2 | 0 | 0 | 0 |
| Sex: Female, Male: Female | Participants | 19 | 100 | 123 | 5 | 138 | 23 |
| Sex: Female, Male: Male | Participants | 11 | 74 | 85 | 4 | 115 | 26 |
| Ethnicity (NIH/OMB): Hispanic or Latino | Participants | 6 | 35 | 34 | 3 | 136 | 19 |
| Ethnicity (NIH/OMB): Not Hispanic or Latino | Participants | 24 | 138 | 173 | 6 | 117 | 30 |
| Ethnicity (NIH/OMB): Unknown or Not Reported | Participants | 0 | 1 | 1 | 0 | 0 | 0 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 0 | 0 | 1 | 0 | 0 | 1 |
| Race (NIH/OMB): Asian | Participants | 1 | 11 | 10 | 0 | 4 | 2 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 0 | 0 | 2 | 0 | 0 | 0 |
| Race (NIH/OMB): Black or African American | Participants | 3 | 23 | 27 | 7 | 87 | 16 |
| Race (NIH/OMB): White | Participants | 26 | 135 | 164 | 2 | 162 | 30 |
| Race (NIH/OMB): More than one race | Participants | 0 | 5 | 3 | 0 | 0 | 0 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 1 | 0 | 0 | 0 |
6. Primary Endpoint
The registry lists the primary outcome as Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSA, measured over Day 1 to Day 7 after vaccination.
| Element | Registry entry |
|---|---|
| Result type | Number |
| Measure of spread | 95% Confidence Interval |
| Unit | Percentage of participants |
| Endpoint classification | Binary Endpoint |
The named primary endpoint is the percentage of participants in Substudy A who experienced at least one local reaction during Day 1 to Day 7 after vaccination. The reactions include pain at the injection site, redness, and swelling. Participants recorded reactions in an electronic diary; reactions could also be recorded as adverse events in the case report form. The registry says the analyzed number represents participants reporting at least one electronic-diary response, an important qualification when interpreting the denominator.
The endpoint is a binary participant-level outcome: a participant either had a recorded local reaction within the defined period or did not. Expressing the result as a percentage makes the frequency interpretable within the analyzed group. The confidence interval describes uncertainty around that estimated percentage; it is not a range containing a known fixed percentage with certainty, and it does not address bias or confounding.
Redness and swelling were measured in measuring-device units, with 1 mdu equal to 0.5 centimeter. The registry describes severity grades for redness and swelling as mild when greater than 2.0 to 5.0 cm, moderate when greater than 5.0 to 10.0 cm, severe when greater than 10.0 cm, and Grade 4 for specified forms of necrosis or exfoliative dermatitis. Injection-site pain was graded by its effect on activity, with Grade 4 defined as an emergency room visit or hospitalization for severe pain. The numerical percentage and its 95% confidence interval are not reported in the registry record.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry identifies a primary endpoint for local reactions in Substudy A, but the numerical result for that endpoint is not reported in the registry record. No primary percentage, confidence interval, or associated test result is available in the posted results described by the record. Consequently, the frequency and precision of local reactions for that endpoint cannot be characterized from these registry entries. The named endpoint and its measurement rules describe what was intended to be summarized, not the observed estimate.
The safety information is reported separately by substudy and age group. For serious adverse events, the listed counts were 1 of 30 in SSA Group 1, 0 of 174 in SSA Group 2, and 4 of 208 in SSA Group 3. In SSB, the counts were 0 of 9, 2 of 253, and 1 of 49 across its three listed age groups. In SSC, the counts were 0 of 18 in Cohort 2 aged 12 to 17 years, 1 of 92 in the combined Cohort 1 and Cohort 2 group aged 18 to 55 years, 3 of 106 in the corresponding group older than 55 years, 0 of 51 in Cohort 3 aged 18 to 55 years, and 1 of 51 in Cohort 3 older than 55 years. These are group-specific counts, not estimates of comparative treatment effects.
The registry also lists other adverse events by group, with counts ranging from 4 of 9 in SSB Group 1 to 166 of 253 in SSB Group 2. These counts should be read in the context of the registry’s categories and the listed denominators. The record does not give a causal assessment for each event in the information; indeed, the findings should not be interpreted as establishing that an event was caused by a vaccine candidate.
One death is listed in SSA Group 3 and one in the SSC combined 18-to-55-year and older-than-55-year group for participants older than 55 years. The counts alone do not establish cause or relationship to vaccination. The record does not report further details about these deaths in the registry record.
Overall, the posted information supports a descriptive reading of outcomes across enrolled groups, not a claim that one candidate is safer or more effective than another. There is no randomized control group, and the numerical primary local-reaction result is unavailable. The study’s stated broader aims include immunogenicity, but antibody or other immunogenicity results are not reported in the registry record.
9. Statistical Methods Explained
The main endpoint is a binary outcome summarized as a percentage of participants. In general, such an estimate is formed by identifying participants with the event and relating that count to the analyzed population. The registry describes the primary endpoint as the percentage with at least one local reaction, and states that the analyzed number refers to participants reporting at least one electronic-diary response. This denominator definition matters: people with no recorded response may not be equivalent to people who recorded no reaction.
What does a confidence interval express?
The registry identifies a 95% confidence interval as the uncertainty measure for the primary percentage. In general, a confidence interval gives a range of estimates compatible with the observed data under the method’s assumptions. A narrower interval indicates greater statistical precision than a wider interval, but precision is not the same as freedom from bias. A confidence interval also does not establish causality or show how the result would compare with an untreated or alternative-treatment group.
The registry record does not report the primary endpoint’s percentage or its confidence limits, so neither the estimate nor its precision can be described numerically. The specific method used to calculate that interval is not reported in the registry record. It would therefore be inappropriate to assign a particular interval procedure to the sponsor’s analysis.
Why do the analysis population and recording process matter?
The primary endpoint population is described as the safety population, defined as participants who received the study intervention. For this endpoint, the registry further clarifies that the overall number analyzed signifies participants reporting at least one electronic-diary response. Those statements describe both a treatment-exposure criterion and a response-recording criterion. They do not, by themselves, explain how participants with incomplete diary entries were handled or how any missing observations were treated.
Reactions could be recorded in an electronic diary or as adverse events in the case report form. These are different recording routes, and the registry’s endpoint definition emphasizes diary responses for the analyzed participant number. The details of how the two sources were reconciled, how duplicate reports were handled, or how observations outside the diary were incorporated are not reported in the registry record. General statistical practice would seek consistent rules for event ascertainment and participant inclusion, but the record does not establish which additional rules were used.
Why are these groups not treatment comparisons?
Allocation is listed as not applicable and the model as single group. There is no randomized control arm. The substudies also differ in prior COVID-19 vaccination or exposure, age eligibility, and candidate assigned by cohort. In general, an unadjusted comparison across groups with different characteristics can mix treatment differences with baseline and design differences. The group-specific counts are therefore descriptive and should not be read as evidence that one candidate caused more or fewer events than another.
The registry reports 30 outcome measures and 2 analyses. The details of the analysis methods, the mapping of analyses to outcomes, and any prespecified hierarchy are not reported in the registry record. A complete statistical analysis plan, including any adjustment or model specifications, is not reported in the registry record.
What does over-dispersion mean in general?
For binary outcomes, a simple model can sometimes understate variability when observations are more heterogeneous than the model assumes. In general, over-dispersion means the observed variation exceeds the variation expected under a specified model, which can make standard errors too small and confidence intervals too narrow if ignored. The record does not report an over-dispersion assessment or a model for this primary endpoint, so there is no basis to say whether it was present or how it was addressed.
How should planning calculations be understood?
Any sample-size figures in the accompanying analysis are planning illustrations rather than observed power. The stated illustration assumptions use a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the effect to detect set as a stated fraction of an observed effect. The registry design itself is single group, and these assumptions do not describe its allocation. The illustrations are not a retrospective probability that the study detected an effect, nor are they the trial’s own sample-size justification. The trial’s own sample-size justification is not reported in the registry record.
In general, planning calculations depend on assumptions about the outcome, effect size, variability, significance level, and allocation. If those assumptions differ from actual study conditions, the resulting planning figures may not describe the operating characteristics of the completed study. The assumptions and calculated values should therefore be kept distinct from the posted observations. No numerical planning result is stated in the registry entries used for this explanation.
No interim analyses, stopping rules, or formal hypothesis-testing strategy are reported in the registry record. Without those details, the analysis should be interpreted through the outcome definitions and descriptive counts that are available, rather than through an assumed inferential plan.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists 30 outcome measures and 2 analyses, but the details of how the analyses relate to the outcomes are not reported in the registry record. The record does not state whether outcomes were prioritized beyond identifying the local-reaction measure as primary, whether any hierarchy was used, or whether statistical tests or confidence intervals were adjusted for multiple outcomes or comparisons. Because many outcomes may be examined, multiplicity can increase the chance of at least one apparently unusual result when many tests are conducted. General methods to address this include prespecifying a small number of primary questions or adjusting inference, but there is no basis to say which approach was used for this study.
The primary population is described as participants who received the intervention, with the endpoint’s analyzed count referring to participants who reported at least one electronic-diary response. The registry record does not report how missing diary days, incomplete records, or participants without any diary response were handled in the endpoint estimate. It also does not report imputation methods, sensitivity analyses for missing data, or whether missingness was assessed by group. These omissions affect how fully the endpoint can be interpreted, because a missing record is not necessarily equivalent to the absence of a reaction.
The safety population includes participants who received study intervention. Further analysis-population definitions for the other outcomes are not reported in the registry record. The record also does not report a detailed statistical analysis plan, interim analysis procedures, or a prespecified approach for multiple testing. In the absence of these details and the primary numerical result, multiplicity and missing-data effects cannot be evaluated from the registry entries.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| SSA - Group 1: 12-17 Years | 1 | 30 | 3.3% |
| SSA - Group 2: 18-55 Years | 0 | 174 | 0.0% |
| SSA - Group 3: >55 Years | 4 | 208 | 1.9% |
| SSB - Group 1: 12-17 Years | 0 | 9 | 0.0% |
| SSB - Group 2: 18-55 Years | 2 | 253 | 0.8% |
| SSB - Group 3: >55 Years | 1 | 49 | 2.0% |
| SSC - Cohort 2: 12-17 Years | 0 | 18 | 0.0% |
| SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years | 1 | 92 | 1.1% |
| SSC - Cohort 1 and Cohort 2 Combined: >55 Years | 3 | 106 | 2.8% |
| SSC - Cohort 3: 18-55 Years | 0 | 51 | 0.0% |
| SSC - Cohort 3: >55 Years | 1 | 51 | 2.0% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| SSA - Group 1: 12-17 Years | 0 of 30 |
| SSA - Group 2: 18-55 Years | 0 of 174 |
| SSA - Group 3: >55 Years | 1 of 208 |
| SSB - Group 1: 12-17 Years | 0 of 9 |
| SSB - Group 2: 18-55 Years | 0 of 253 |
| SSB - Group 3: >55 Years | 0 of 49 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 1% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| SSA - Group 1: 12-17 Years | 27 of 30 |
| SSA - Group 2: 18-55 Years | 154 of 174 |
| SSA - Group 3: >55 Years | 134 of 208 |
| SSB - Group 1: 12-17 Years | 4 of 9 |
| SSB - Group 2: 18-55 Years | 166 of 253 |
| SSB - Group 3: >55 Years | 25 of 49 |
Most frequent serious adverse event terms
| Event term | Organ system | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | SSB - Group 1: 12-17 Years | SSB - Group 2: 18-55 Years | SSB - Group 3: >55 Years |
|---|---|---|---|---|---|---|---|
| Cardiac arrest | Cardiac disorders | 0 of 30 | 0 of 174 | 1 of 208 | 0 of 9 | 0 of 253 | 0 of 49 |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | 0 of 30 | 0 of 174 | 1 of 208 | 0 of 9 | 0 of 253 | 0 of 49 |
| Acute kidney injury | Renal and urinary disorders | 0 of 30 | 0 of 174 | 1 of 208 | 0 of 9 | 0 of 253 | 0 of 49 |
| Paroxysmal nocturnal haemoglobinuria | Renal and urinary disorders | 0 of 30 | 0 of 174 | 1 of 208 | 0 of 9 | 0 of 253 | 0 of 49 |
| Hyponatraemia | Metabolism and nutrition disorders | 0 of 30 | 0 of 174 | 1 of 208 | 0 of 9 | 0 of 253 | 0 of 49 |
| Cellulitis | Infections and infestations | 1 of 30 | 0 of 174 | 0 of 208 | 0 of 9 | 0 of 253 | 0 of 49 |
| Invasive lobular breast carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0 of 30 | 0 of 174 | 1 of 208 | 0 of 9 | 0 of 253 | 0 of 49 |
| Small intestinal obstruction | Gastrointestinal disorders | 0 of 30 | 0 of 174 | 0 of 208 | 0 of 9 | 0 of 253 | 1 of 49 |
| Appendicitis | Infections and infestations | 0 of 30 | 0 of 174 | 0 of 208 | 0 of 9 | 1 of 253 | 0 of 49 |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | 0 of 30 | 0 of 174 | 0 of 208 | 0 of 9 | 1 of 253 | 0 of 49 |
Most frequent non-serious adverse event terms
| Event term | Organ system | SSA - Group 1: 12-17 Years | SSA - Group 2: 18-55 Years | SSA - Group 3: >55 Years | SSB - Group 1: 12-17 Years | SSB - Group 2: 18-55 Years | SSB - Group 3: >55 Years |
|---|---|---|---|---|---|---|---|
| Injection site pain (PAIN) | General disorders | 24 of 30 | 132 of 174 | 107 of 208 | 4 of 9 | 142 of 253 | 18 of 49 |
| Fatigue (FATIGUE) | General disorders | 17 of 30 | 99 of 174 | 73 of 208 | 1 of 9 | 87 of 253 | 12 of 49 |
| Headache (HEADACHE) | Nervous system disorders | 11 of 30 | 76 of 174 | 54 of 208 | 1 of 9 | 76 of 253 | 8 of 49 |
| Myalgia (MUSCLE PAIN) | Musculoskeletal and connective tissue disorders | 7 of 30 | 38 of 174 | 25 of 208 | 1 of 9 | 45 of 253 | 9 of 49 |
| Diarrhoea (DIARRHEA) | Gastrointestinal disorders | 0 of 30 | 21 of 174 | 18 of 208 | 1 of 9 | 42 of 253 | 4 of 49 |
| Arthralgia (JOINT PAIN) | Musculoskeletal and connective tissue disorders | 5 of 30 | 25 of 174 | 16 of 208 | 1 of 9 | 32 of 253 | 6 of 49 |
| Chills (CHILLS) | General disorders | 6 of 30 | 16 of 174 | 19 of 208 | 1 of 9 | 30 of 253 | 5 of 49 |
| Injection site swelling (SWELLING) | General disorders | 5 of 30 | 13 of 174 | 12 of 208 | 1 of 9 | 30 of 253 | 5 of 49 |
| Injection site erythema (REDNESS) | General disorders | 3 of 30 | 7 of 174 | 12 of 208 | 0 of 9 | 22 of 253 | 1 of 49 |
| Pyrexia (FEVER) | General disorders | 5 of 30 | 7 of 174 | 8 of 208 | 1 of 9 | 6 of 253 | 3 of 49 |
Serious events with the highest arm-level rate: cellulitis (3.3%), small intestinal obstruction (2.0%), cerebrovascular accident (2.0%), diverticulitis (1.1%), cervical vertebral fracture (0.9%).
The serious adverse event figures are counts of participants with an event alongside the number at risk for each listed group. For example, the registry lists 1 of 30 in SSA Group 1 and 4 of 208 in SSA Group 3; several groups have zero listed serious adverse events. These observations describe the groups as recorded and should not be combined into an assumed treatment comparison. Their denominators differ, and the groups also differ in age, substudy, and candidate.
The registry lists serious adverse event terms including Cellulitis at 3.3%, Small intestinal obstruction at 2.0%, Cerebrovascular accident at 2.0%, Diverticulitis at 1.1%, Cervical vertebral fracture at 0.9%, and Road traffic accident at 0.9%. The record excerpt does not explain the denominator or event-counting method for each term beyond listing these terms and percentages. The percentages should therefore be read as reported, without deriving additional rates or assuming the terms represent mutually exclusive participants.
A serious adverse event count does not establish that the intervention caused the event. The listed data do not provide a causal assessment or detailed case narratives. Deaths are listed in two age-defined groups, but the counts alone do not identify causes or relationships to vaccination. Those details are not reported in the registry record.
12. What the Result Does, and Does Not, Mean
The record describes a completed study that assessed BNT162b2 vaccine candidates in several participant groups and recorded safety outcomes. Its primary endpoint is clearly defined as the percentage of Substudy A participants with a local reaction during the first 7 days after vaccination, with a 95% confidence interval intended as the uncertainty measure. However, the endpoint’s observed percentage and confidence interval are not reported in the registry record. That absence prevents a numerical assessment of the frequency or precision of the primary result.
The listed serious adverse event and other adverse event counts provide descriptive information for each subgroup. They do not show what would have happened to comparable participants without vaccination or with a different candidate. Since the study is single group, with no randomized control comparison, the counts cannot isolate the effect of the candidate from other explanations. Differences between substudies may reflect their different eligibility criteria, age groups, prior vaccination or exposure histories, or other factors.
The study’s stated purpose includes immunogenicity, but immunogenicity results are not reported in the registry record. The registry excerpt also does not provide numerical findings for the primary local-reaction endpoint. Consequently, the information cannot establish the comparative performance of the candidates, quantify their immunogenicity, or support a causal conclusion about adverse events.
These limitations do not make the reported counts meaningless: they document what was recorded within the groups and provide a descriptive account of the safety data in the registry. They do, however, set boundaries on interpretation. Observed counts are not treatment-effect estimates, and the absence of a reported primary result is not evidence of either a high or low reaction frequency.
13. Why This Trial Matters Statistically
This study is statistically notable for combining several vaccine candidates and participant populations within a single-group Phase 2/3 design. That structure makes the distinctions among substudy, cohort, age, and prior vaccination or exposure particularly important. The listed groups provide descriptive safety information, but they do not create randomized comparisons. Statistical interpretation must preserve that distinction rather than treating the group labels as interchangeable arms of a controlled trial.
The primary endpoint also illustrates why outcome definitions and denominators matter. It is not simply a count of reaction reports: it is a participant-level percentage over a specific post-vaccination period, with the analyzed number tied to participants reporting at least one electronic-diary response. Understanding whether participants have complete records, partial records, or no response is essential to interpreting an estimate. The registry record does not provide the numerical estimate or explain missing diary handling, limiting assessment of both magnitude and precision.
Finally, the study’s broader aims encompass safety, tolerability, and immunogenicity, while the registry entries give group-level adverse event counts and a named primary endpoint without its result. The separation between an intended outcome and a posted numerical result is consequential: endpoint definitions alone cannot answer how frequently outcomes occurred. The registry record’s limits also underscore why a full analysis plan and complete outcome reporting are useful for evaluating multiplicity, missing data, and the scope of conclusions.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The most direct limitation is that the numerical result for the named primary endpoint is not reported in the registry record. Without the percentage and its 95% confidence interval, the primary local-reaction frequency and its statistical precision cannot be evaluated. The broader summary also ends during its description of Substudy C, so full details of that substudy’s procedures are not reported in the registry record.
The study has no randomized control group and is listed as single group with allocation not applicable. The different vaccine candidates are assigned across substudies and cohorts with differing age and eligibility descriptions, so observed differences cannot be attributed to the candidate alone. The registry entries do not provide immunogenicity results, detailed causal assessments for serious events, or further information about the deaths listed in two groups.
Important analysis details are also not reported in the registry record: the method for calculating the primary confidence interval, handling of missing or incomplete diary responses, adjustment for multiple outcomes, detailed statistical analysis plan, and sample-size justification. Although the primary endpoint’s population is described, the response-based denominator warrants caution when interpreting any percentage. These limits constrain evaluation of the primary outcome and the strength of conclusions that can be drawn from the descriptive safety counts.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals — NCT05997290.
- Registry record last updated 2026-04-28; status last verified 2026-04.
- Results first posted 2026-04-28.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
NCT05997290 is a completed Phase 2/3, single-group study sponsored by BioNTech SE, with enrollment of 1051. It evaluated BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), and BNT162b2 (Omi KP.2) in several substudies and age-defined groups. The described arms received a single 30 µg dose at Visit 1; the registry lists no masking and no randomized allocation.
The named primary endpoint is the percentage of Substudy A participants with local reactions during Day 1 to Day 7 after vaccination, with a 95% confidence interval. The numerical primary result is not reported in the registry record. Serious adverse event and other adverse event counts are listed by group, but they are descriptive and do not constitute randomized comparisons. The registry record does not report the detailed analysis plan, missing-data procedures, or multiplicity approach.